Clinical Trials · NCT07874828

PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

Name: PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 2Tirzepatide

Phase: Phase 2
Recruitment status: Recruiting
Sponsor: M.D. Anderson Cancer Center
Enrollment: 30
Start date: Oct 2026
Locations: 1 site, United States
Primary endpoint: Safety and Adverse Events (AEs)

View Tirzepatide compound reference